A Randomized, Double-blind, Single-dummy, Positive Drug and Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of Hemay005 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Mufemilast (Primary) ; Roflumilast
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Ganzhou Hemay Pharmaceutical
Most Recent Events
- 06 Jan 2026 New trial record